Page 85 - Read Online

Nguyen et al. J Transl Genet Genom 2018;2:19 I http://dx.doi.org/10.20517/jtgg.2018.20 Page 11 of 11

21. O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology
2016;280:576-84.
22. Baselga J, Gómez P, Greil R, Braga S, Climent MA, et al. Randomized phase II study of the anti-epidermal growth factor receptor
monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin
Oncol 2013;31:2586-92.
23. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the
efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Lancet Oncol 2010;11:753-62.
24. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal
cancer. N Engl J Med 2013;369:1023-34.
25. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. American Society of Clinical Oncology provisional clinical
opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth
factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
26. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive,
estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19:5505-12.
27. Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, et al. A phase II trial of abiraterone acetate plus prednisone in patients with
triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol 2016;27:812-8.
28. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, et al. Identification of molecular apocrine breast tumours by
microarray analysis. Oncogene 2005;24:4660-71.
29. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, et al. Molecular apocrine breast cancers are aggressive estrogen
receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 2013;15:R37.
30. Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, et al. Targeted NGS, array-CGH, and patient-derived tumor xenografts for
precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget 2016;7:79428-41.
31. Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in
colorectal cancers. Nat Commun 2015;6:8305.
32. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-
derived xenograft models identify second-line combination therapies. Clin Cancer Res 2016;22:1592-602.